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esponsibility of InstAbstract Zidovudine (AZT), the ﬁrst drug approved by the US Food and Drug Administration for the
treatment of human immunodeﬁciency virus (HIV) infection, is metabolized in the host cells to 5′-AZT
triphosphate (AZT-TP) which inhibits HIV reverse transcriptase. As the pharmacokinetics of AZT and its
phosphorylated metabolites in human peripheral blood mononuclear cells (hPBMCs) is limited, the aim of
this study was to determine the pharmacokinetic parameters of AZT and its phosphorylated metabolites in
hPBMCs from 12 healthy Chinese male subjects after a single oral dose of 600 mg of AZT. Blood
samples were collected prior to drug administration, then at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8 and 10 h
after drug administration. Mononuclear cells collected by Ficoll-Hypaque density gradient centrifugation
were used for determination of AZT and metabolites [AZT monophosphate (AZT-MP), AZT diphosphate
(AZT-DP) and AZT-TP] and the plasma was used to evaluate the pharmacokinetics of AZT. Plasma
concentration of AZT peaked within 0.583 h and intracellular concentrations of AZT, AZT-MP, AZT-DP
and AZT-TP peaked within 1.083, 1.500, 1.417 and 1.583 h, respectively. AZT in plasma was eliminated
rapidly with t1/2 of 2.022 h, and AZT-MP, AZT-DP and AZT-TP were eliminated with t1/2 of 13.428,
8.285 and 4.240 h, respectively. The plasma concentration of the phosphorylated metabolites was not
quantiﬁable.
& 2016 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical
Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).2
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Table 1 Baseline demographic characteristics of volunteers.
Parameter Valuea Range
Age (year) 23.171.5 20–28
Height (m) 1.770.1 1.60–1.84
Body weight (kg) 64.873.0 49–78
aEach value represents the Mean7SD, n¼12.
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Nucleoside reverse transcriptase inhibitors (NRTIs) were the ﬁrst
agents shown to be safe and effective for the treatment of patients
infected with HIV, and they remain cornerstones of most treatment
regimens today. These drugs are selectively phosphorylated to
their active triphosphate moieties (NRTI-TP) in human peripheral
blood mononuclear cells (hPBMCs)1. Zidovudine (3'-azido-
3'-deoxythymidine, AZT) was the ﬁrst drug for the treatment of
human immunodeﬁciency virus (HIV) infection approved by the
US Food and Drug Administration (FDA). The parent compound
AZT must be metabolized in the host cells to 5'-AZT triphosphate
(AZT-TP), which acts as a competitive inhibitor of HIV reverse
transcriptase or is incorporated into the viral genome, terminating
DNA chain elongation2,3. It remains an important NRTI compo-
nent of many ﬁrst-line highly active antiretroviral therapies
(HAART) used today4.
AZT is converted inside the cell into AZT monophosphate
(AZT-MP) by thymidine kinase. Thymidylate kinase in turn
converts AZT-MP into AZT diphosphate (AZT-DP), which is
further phosphorylated to AZT-TP, presumably by pyrimidine
nucleoside diphosphate kinase. AZT monophosphate is the pre-
dominant compound in human cells exposed to AZT, suggesting
that thymidylate kinase is the rate limiting enzyme in the synthesis
of active AZT-TP2,5. Most measurements of AZT are performed in
plasma or serum, but because AZT is phosphorylated to its active
form inside the cells, measurements of plasma levels of AZT may
not directly correlate with antiviral activity or toxicity. Therefore,
it is important to determine the intracellular levels of AZT and its
metabolites.
Recently, several studies have shown that the intracellular
concentration of the triphosphate moieties of NRTIs correlated
better with the virologic response than did the levels of the parent
compound in plasma6,7. Long-term use of high-dosage AZT
caused damage to many tissues, including a mitochondrial skeletal
muscle myopathy, a dilated cardiomyopathy and hepatotoxicity
associated with mitochondrial DNA depletion8. These conditions
are related to AZT use and not to the progression of acquired
immunodeﬁciency syndrome (AIDS) since when patients experi-
encing one or more of these adverse effects discontinued AZT
therapy, the adverse effects would resolve9,10. In modern ther-
apeutic regimens, AZT is given at much lower doses and in
combination with other drugs. Thus, these adverse effects have
become fairly rare, but hematological toxicities, such as anemia
and lipodystrophy are observed commonly in combination thera-
py11-13.
Detection and quantitation of the NRTI-TP concentrations in
hPBMCs will lead to a better understanding of the pharmacoki-
netic and pharmacodynamic characteristics of these agents, which
will optimize treatment with AZT or combination therapy. The
measurement of AZT-TP remains difﬁcult because of the inter-
ference from endogenous nucleoside triphosphates. In this study,
the pharmacokinetics of AZT and its phosphorylated metabolites
was determined in hPBMCs.2. Materials and methods
2.1. Materials and subjects
Zidovudine tablets (300 mg) were purchased from Northeast
Pharmaceutical Group Shenyang No. 1 Pharmaceutical Co., Ltd.(Shenyang, China). Reference material of Zidovudine was pur-
chased from Yidu HEC Pharma Co., Ltd. (Wuhan, China).
Reference material of Zidovudine phosphate compounds was
purchased from Moravek Biochemicals (CA, USA). All other
reagents were commercially available and of analytical grade.
Twelve healthy Chinese male subjects were recruited and
assessed for inclusion in the study. The subjects were underwent
a standardized screening procedure to conﬁrm their eligibility. The
demographic characteristics of the study group are given in
Table 1. All subjects gave their written informed consent to
participate in the study after they had been well informed about the
study objectives, method and possible risks. After a physical
examination, subjects with any abnormality of the cardiovascular,
respiratory, abdominal or central nervous system were excluded.
Blood pressure (BP) and heart rate (HR) were measured. Addi-
tionally, an electrocardiogram was conducted and a general
examination of the subject was performed to exclude any illness
or abnormality.
2.2. Study design
This study was carried out in accordance with the International
Conference on Harmonization (ICH) guidance on general con-
siderations for clinical trials14. The dose in this study was selected
based on the daily dosage regimen of AZT (600 mg) according to
the terms of safety and therapeutic efﬁcacy. The pharmacokinetics
of AZT was determined following the administration of a single
oral dose of 600 mg of AZT. An open-label design was used to
evaluate the pharmacokinetics of AZT in the selected subjects after
an overnight fast of at least 12 h. They received a single oral dose
of 600 mg AZT followed by 240 mL of water. They received
standardized meals 4 h and 10 h after drug administration.
2.3. Sample collection
For the pharmacokinetic assessments, blood samples (20 mL) were
collected from an indwelling intravenous catheter inserted into the
antecubital vein of the forearm of each subject prior to drug
administration (blank), then at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6,
8 and 10 h after drug administration in heparinized tubes. The
blood samples were centrifuged and the plasma was harvested and
transferred to polystyrene microcentrifuge tubes and stored at
–20 1C until assay.
The remaining blood cells without plasma are used for the
separation of mononuclear cells by the Ficoll-Hypaque density-
gradient centrifugation method. First, the blood cells were diluted
(1:1 blood cells/diluted solution). Second, a volume of 3–4 mL
Ficoll-Hypaque solution was added into 15-mL conical centrifuge
tubes using a sterile pipet, then the diluted blood cells (6–8 mL)
were slowly layered by placing the tip of the pipet containing the
diluted blood cells 0.7–1.5 cm above the level of Ficoll-Hypaque
Figure 1 Plasma concentration-time curve of AZT in healthy
Chinese subjects after a single-dose oral administration of 600 mg
AZT. Values are Mean7SD, n¼12.
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2000 rpm (900 g) for 15 min with no break. Last, the mono-
nuclear lymphocyte cell layer was transferred to a centrifuge tube.
The layer will appear as a white, cloudy band between the blood
cells and the Ficoll-Hypaque layers. Then the cells were washed
by adding Hanks' balanced salt solution (3 times the volume of the
mononuclear cell layer) and centrifuged for 20 min at 1800 rpm.
The precipitate is the mononuclear cells. After removing the
supernatant, the mononuclear cells were re-suspended in 5 mL
Hanks' balanced salt solution. The cells were counted by using
100 μL cell resuspension solution, and the remaining cell resus-
pension solution was used to recover the mononuclear cells by
centrifugation. To store the cells, methyl alcohol–water (7:3,
–20 1C) was added to lyse the cells and 50 mmol/L sodium
orthovanadate was added as a phosphatase inhibitor. The cells
were stored at –80 1C until use. The mononuclear cells were used
for concentration determination of AZT, AZT-MP, AZT-DP and
AZT-TP by a validated LC-MS/MS method.
2.4. Bioanalytic assessments
The level of AZT and its phosphorylated metabolites in plasma
and mononuclear cells was determined by a validated LC–MS/MS
method15. Brieﬂy, the separation of the analytes was achieved on a
Phenomenex Gemini-C18 column with 0.2% formic acid solution
and methanol as the mobile phase. AZT was detected by
electrospray ionization-tandem mass spectroscopy in the multi-
ple-reaction-monitoring positive mode. The precursor-product ion
transitions monitored were m/z 267.9-126.8 for zidovudine and
m/z 247.9-126.8 for the internal standard tinidazole. The
calibration curve of AZT-TP was established over the range of
0.1125–82.05 pg/μL (r2¼0.9941). The lower limit of quantiﬁca-
tion (LLOQ) was 0.1125 pg/μL. The intra- and inter-day precision
(RSD) was less than 8.0%, the average extraction recoveries and
the matrix effects were satisﬁed with the requirements of biolo-
gical sample measurement. The concentration of the quality
control samples was 1.013, 9.117 and 82.05 pg/μL. The absence
of interference of AZT with tinidazole was veriﬁed.3. Results and discussion
The study enrolled 12 subjects and all of them completed the
study. Safety proﬁles and pharmacokinetic characteristics were
assessed in all subjects who completed the study. In the present
study, measures were taken to protect the safety of the subjects,
including prolonging the time of lying in bed and remaining in the
clinical research unit, and enhancing the clinical monitoring and
nursing. All subjects were negative for hepatitis and HIV. None of
the 12 subjects had hypersensitivity to AZT.
None of the enrolled subjects showed any signs of serious
adverse drug reactions (ADRs) during or after the study. AZT
was well tolerated in the participating subjects. The most
commonly reported ADRs associated with AZT administration
were headache (one report) and nausea (one report), which are
well-known ADRs associated with AZT. Physical examination,
electrocardiograms and laboratory tests revealed no clinically
signiﬁcant changes.
The mean linear and plasma concentration-time curve of AZT
administered orally as a single dose are presented in Fig. 1. The
mean linear and intracellular concentration-time curve of AZT,
AZT-MP, AZT-DP and AZT-TP are presented in Fig. 2. Theaverage non-compartmental pharmacokinetic parameters of AZT,
AZT-MP, AZT-DP and AZT-TP in hPBMCs are summarized in
Table 2. Pharmacokinetic parameters of AZT in plasma are
summarized in Table 3.
The present study evaluated the pharmacokinetics of AZT in
plasma and pharmacokinetics of AZT, AZT-MP, AZT-DP and
AZT-TP in hPBMCs. After oral administration of AZT, its
appearance in plasma was rapid and its plasma concentration
peaked within 0.583 h; the intracellular concentration of AZT,
AZT-MP, AZT-DP and AZT-TP peaked within 1.083, 1.500,
1.417 and 1.583 h, respectively, and these differences result from
the distribution and transformation of AZT in vivo. AZT was
eliminated with an apparent t1/2 of 2.493 h in hPBMCs, and was
longer than that of plasma (2.022 h) due to transfer of AZT from
plasma to cells. AZT-MP, AZT-DP and AZT-TP were eliminated
with t1/2 of 13.428, 8.285 and 4.24 h respectively, indicating that
AZT in plasma was eliminated rapidly, and metabolized to AZT-
MP, AZT-DP and AZT-TP in hPBMCs rapidly after oral admin-
istration. The AUC value of AZT-MP was 2.548 (ngUh)/106cell,
more than that of other phosphate metabolites and the parent drug
in hPBMCs after oral administration. On the other hand, the
plasma concentration of the phosphate metabolites was not
quantiﬁable, indicating AZT was metabolized in hPBMCs instead
of plasma. All NRTI antiretroviral agents, while differing in
pharmacokinetics, toxicity and efﬁcacy, require conversion to the
triphosphate form in order to inhibit viral replication. Efﬁcacy of
this class of compounds depends on many factors including parent
drug pharmacokinetics (absorbance, clearance, etc.), intracellular
metabolism factors such as transport to the cell, multi-step
phosphorylation and de-phosphorylation or other enzymatic pro-
cesses, and the activation status of cells16. AZT was converted to
AZT-MP in cells by thymidine kinase, then to AZT-DP by
thymidylate kinase, and further to its active form of AZT-TP
presumably by pyrimidine nucleoside diphosphate kinase. Pre-
vious studies have shown that intracellular concentrations of AZT-
TP correlated with anti-viral activity and immunological response
to therapy17. No AZT-TP was detected during the incubation in
either liver or heart mitochondria18. This may be due to the limited
time frame in which isolated mitochondria may be studied and to
the poor reactivity of AZT-MP with thymidylate kinase. In non-
mitotic cells, like those found in heart and liver, no thymidine
Figure 2 Concentration-time curves of AZT and its phosphate metabolites in hPBMCs after a single-dose oral administration of 600 mg AZT.
Values are Mean7SD, n¼12.
Table 2 Pharmacokinetic parameters of AZT and its phosphorylated metabolites in HPBMCs after a single-dose oral administration of
600 mg AZT.
Parameter AZT AZT-MP AZT-DP AZT-TP
Cmax (ng/10
6 cell) 0.17570.018 0.92270.115 0.07670.010 0.06270.012
Tmax (h) 1.08370.289 1.50071.500 1.41770.195 1.58370.289
AUC0-t (ngUh/10
6 cell) 0.37170.193 2.54870.656 0.34570.055 0.22370.043
AUC0-1 (ngUh/10
6 cell) 0.39670.189 6.34372.964 0.61570.161 0.27970.069
t1/2 (h) 2.49370.638 13.42879.611 8.28572.840 4.24070.977
MRT0-t (h) 4.941719.287 4.19070.347 0.792712.028 3.87270.235
MRT0-1 (h) 14.853732.375 18.715712.856 14.27076.350 6.32871.137
Each value represents the mean7SD, unless otherwise speciﬁed; n¼12.
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phosphorylate thymidine is by the mitochondrial thymidine kinase
2 pathways19. AZT, by acting to inhibit thymidine kinase 2, may
greatly reduce the conversion of thymidine to AZT-MP. Reduction
in the production of AZT-MP directly results in a reduction in
AZT-TP production, as AZT-MP is a necessary precursor to AZT-
TP. As AZT-TP becomes limiting, mitochondrial DNA replication
slows, and eventually mitochondrial DNA depletion is evident.
Further evaluation of this potential mechanism will require studies
to correlate the depletion of thymidine triphosphate pools with
cytotoxicity, mitochondrial toxicity and mitochondrial DNA
depletion, perhaps in hepatocyte or cardiomyocyte cell culture.
These pharmacokinetic studies on the metabolism of AZT to AZT-TP in hPBMCs should lead to a better understanding of the
pharmacokinetic and pharmacodynamic characteristics of this drug
class, and better treatment of viral infections.4. Conclusions
This study demonstrated that AZT phosphate metabolites (AZT-
MP, AZT-DP and AZT-TP) are not present in measurable levels in
plasma, and AZT was eliminated rapidly, which may lead to an
inaccurate understanding of its pharmacodynamic characteristics.
These results suggest that determination of AZT-TP in hPBMCs is
more accurate in determining pharmacokinetic and pharmacody-
namics proﬁles.
Table 3 Pharmacokinetic parameters of AZT in plasma after
a single-dose administration of 600 mg AZT.
Parameter AZT
Cmax (μg/L) 3505.1767362.932
Tmax (h) 0.58370.195
AUC0-t (μg  h/L) 7050.14271275.517
AUC0-1 (μg  h/L) 7167.96171267.624
t1/2 (h) 2.02270.946
MRT0-t (h) 2.19770.253
MRT0-1 (h) 2.40470.216
Vd/F (L) 263.9087161.840
CL/F (L/h) 86.092714.962
Each value represents the mean7SD, unless otherwise speciﬁed,
n¼12.
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